William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on February 11.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Myles Minter has given his Buy rating due to a combination of factors tied to Dianthus’s lead antibody, claseprubart, which he views as a strong contender for best-in-class status in complement inhibition. He highlights encouraging Phase II data in generalized myasthenia gravis and points to the upcoming interim analysis from the Phase III CAPTIVATE trial in CIDP, scheduled for the second quarter of 2026, as a key value inflection point.
He also underscores additional upside from the multifocal motor neuropathy program, where prior results from a competitor validate complement inhibition in this indication, and from the early-stage DNTH212 bifunctional antibody expected to enter Phase I readout in 2026. In his view, market concerns over theoretical autoimmune safety risks with C1s inhibition are overstated, and the strong efficacy profile, expanding pipeline, and multiple forthcoming catalysts collectively support a favorable risk-reward and justify the Buy rating.
In another report released on February 11, Wedbush also maintained a Buy rating on the stock with a $55.00 price target.